Xu Jing, Chen Aijun, Peng Yuting, Wen Zhuyuan, Huang Kun, Wang Ping
Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China.
College of Pediatric, Chongqing Medical University, Chongqing, People's Republic of China.
Clin Cosmet Investig Dermatol. 2023 Oct 12;16:2841-2846. doi: 10.2147/CCID.S420900. eCollection 2023.
Psoriasis is a common chronic inflammatory skin disease that manifests itself not only on the skin but also on various tissues and organs of the body. While some psoriasis co-morbidities have been investigated, little is known about its association with impairment of renal function. In 2005, the concept of psoriatic nephropathy was first introduced by Indian nephrologists, suggesting a potential relationship between psoriasis and kidney disease. Adalimumab, a fully human recombinant immunoglobulin G1 monoclonal antibody against tumor necrosis factor (TNF)-α, has been shown to be a safe and effective treatment for patients with moderate to severe psoriasis. Here, we present a case of severe plaque psoriasis accompanied with end-stage renal disease (ESRD) treated with adalimumab. Following the case presentation is a discussion of the relationship between psoriasis and chronic kidney disease (CKD) / ESRD and the possible role of biologics in psoriasis-related kidney damage. The aim of this report is to increase dermatologists' awareness of psoriatic nephropathy as a complication of psoriasis and to raise awareness of the use of biologics in psoriasis.
银屑病是一种常见的慢性炎症性皮肤病，不仅表现在皮肤上，还会累及身体的各种组织和器官。虽然已经对一些银屑病合并症进行了研究，但对于其与肾功能损害之间的关联却知之甚少。2005年，印度肾病学家首次提出了银屑病肾病的概念，提示银屑病与肾脏疾病之间可能存在关联。阿达木单抗是一种完全人源化的重组免疫球蛋白G1单克隆抗体，可抗肿瘤坏死因子（TNF）-α，已被证明是治疗中度至重度银屑病患者的一种安全有效的药物。在此，我们报告一例用阿达木单抗治疗的伴有终末期肾病（ESRD）的重度斑块状银屑病病例。病例报告之后是对银屑病与慢性肾脏病（CKD）/ESRD之间关系以及生物制剂在银屑病相关肾损害中可能作用的讨论。本报告的目的是提高皮肤科医生对银屑病肾病作为银屑病并发症的认识，并提高对生物制剂在银屑病治疗中应用的认识。
